Gurugram, 2nd September 2025 — Praxyla Pharmaceuticals is advancing its National Expansion Grid (NEG) to strengthen medicine supply chains in smaller Indian cities. By December 2026, the company expects to cover more than 200 Tier-2 and Tier-3 cities and an additional 350 rural clusters.

The NEG integrates regional distribution hubs, cold-chain facilities and AI-based demand forecasting to match the service levels of metropolitan markets. The company says the program is designed to address structural gaps that leave many secondary markets dependent on lower quality, loosely regulated generics. This limits doctors’ prescribing choices and forces patients to buy what is available locally, even if it is less effective. In several cases, patients travel to larger cities or postpone treatment, adding both cost and risk.

Progress so far

Since its launch, the program has reached 126 cities across 18 states and four union territories. Praxyla has set up 31 regional hubs linked by a centralized inventory platform, reducing inter-city replenishment times to under 24 hours. The company has leased 750,000 square feet of warehouse space and reports 92 per cent product availability in active markets. For local practitioners, this has reduced the need to confirm stock before prescribing.

Next phase priorities

Praxyla’s expansion plan is structured around three operational levers:

1.   Hub-and-spoke distribution with regional hubs on national highways and micro-depots in city centers for rapid last-mile supply.

2.   Embedded clinical engagement through over 1,000 planned prescriber programs and continuing medical education sessions, supported by digital onboarding tools.

3.   Surge readiness with reserve inventory positioned to handle seasonal peaks or emergency demand without disrupting supply.

The company aims to keep delivery times below 30 hours across the entire grid year-round, even during high-demand cycles.

Management perspective

“This is not only about adding locations or isn’t a numbers game,” said Ravindra Ghosh, Vice President – Field Operations at Praxyla. “When a doctor has to settle for a lesser option because the right medicine may not be on the shelf, the patient pays the price. We intend to end that gap.”

Praxyla’s manufacturing focuses on high-purity Active Pharmaceutical Ingredients with low particle size variance underpins the NEG, ensuring consistent product performance across markets.

Business impact

Since the NEG rollout began, prescription volumes from Tier-2 and Tier-3 cities have grown 14 per cent quarter on quarter. Repeat distributor orders are at 36 per cent, with more than 1,800 Stockists currently active. Distributors say consistent supply of quality branded medicines is improving trust with doctors and reducing the need for substitutions.

About Praxyla
 Praxyla Pharmaceuticals works to improve access to quality medicines in underserved markets through integrated distribution, demand forecasting and clinician engagement.